ENO2 and myeloid sarcoma: A recent study examined plasma NSE levels in MS patients over a five-year period and found a strong inverse relationship between serum NSE levels and disease progression [143] as expressed through EDSS and MSSS score changes, thus potentially reflecting a reduced metabolic activity secondary to axonal loss.